Log | Progress In Mind

Log Type	Authored on	Log Message	Log Node	Authored by
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter clicked	Tue, 11/08/2022 - 13:18	Clicked https://za.progress.im/en/event/covid-19-south-africa		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter subscribed	Wed, 10/12/2022 - 13:23	Newsletter subscribed - Progress in Mind Brazil newsletter		Анонимен
User created	Wed, 10/12/2022 - 13:23	User created		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter subscribed	Wed, 10/12/2022 - 13:23	Newsletter subscribed - Progress in Mind SEA		Анонимен
User created	Wed, 10/12/2022 - 13:23	User created		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Fique atualizado em 5 minutos sobre Psiquiatria e Neurologia	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Tue, 08/04/2020 - 14:46	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен

Log Type	Authored on	Log Message	Log Node	Authored by
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter clicked	Tue, 11/08/2022 - 13:18	Clicked https://za.progress.im/en/event/covid-19-south-africa		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter subscribed	Wed, 10/12/2022 - 13:23	Newsletter subscribed - Progress in Mind Brazil newsletter		Анонимен
User created	Wed, 10/12/2022 - 13:23	User created		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter subscribed	Wed, 10/12/2022 - 13:23	Newsletter subscribed - Progress in Mind SEA		Анонимен
User created	Wed, 10/12/2022 - 13:23	User created		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Fique atualizado em 5 minutos sobre Psiquiatria e Neurologia	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened		Анонимен
Newsletter opened	Tue, 08/04/2020 - 14:46	Opened		Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен
Newsletter opened	Wed, 10/12/2022 - 13:23	Opened	Novos medicamentos têm como alvo a CGRP e seus receptores	Анонимен

Patrocinado por

Progress in Mind Brazil

INSCRIÇÃO NEWSLETTER